Imagion Biosystems Appendix 4G and Corporate Governance Statement for the financial year ended 31 December 2018 is available. Download Appendix 4G.
Imagion Biosystems’ IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review
June 3, 2026
Imagion Biosystems, Ltd. (ASX: IBX) has announced that the US Food and Drug Administration (FDA) completed its review of the company’s investigational new drug (IND)